Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 224 of 5804
-
Can a vaccine boost TB treatment? new trial aims to find out
⭐️ VACCINE ⭐️ Not yet recruitingThis study is being done to test an experimental study vaccine compared to a placebo. The experimental study vaccine is called ID93 + GLA-SE. ID93 + GLA-SE has been used in humans in research but has not been approved for use in medical care. This study will be the first to test …
Phase: PHASE2 • Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:05 UTC
-
New trial aims to wipe out hidden leukemia before transplant
Disease control Not yet recruitingThis phase II MyeloMATCH treatment trial compares cytarabine versus (vs.) cytarabine and venetoclax vs. liposome-encapsulated daunorubicin-cytarabine and venetoclax vs. azacitidine and venetoclax for treating patients who have residual disease after treatment for acute myeloid le…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug combo shows promise for Tough-to-Treat stomach cancers
Disease control Recruiting nowThe goal of this clinical study is to learn more about the study drug, Denikitug (DEN, GS-1811), to evaluate the efficacy and safety of Denikitug Monotherapy and Denikitug-based combinations in in participants with human epidermal growth factor receptor 2 (HER2)-Negative, unresec…
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New combo therapy aims to control lung cancer spread in the chest
Disease control Not yet recruitingThis study is designed as a prospective, multi-center investigation to explore the efficacy and safety of furmonertinib combined with upfront thoracic radiotherapy with or without metastatic lesion radiotherapy in subjects with EGFR-mutant NSCLC and malignant pleural effusion (MP…
Phase: PHASE2 • Sponsor: Jiangmen Central Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New Pill-and-Immunotherapy combo aims to shrink melanoma before surgery
Disease control Not yet recruitingThis Phase 2, multi-center, single-arm study evaluates the safety, tolerability, and activity of neoadjuvant PRTX007 in combination with pembrolizumab in participants with resectable Stage III melanoma. Neoadjuvant immunotherapy has demonstrated improved clinical outcomes compare…
Phase: PHASE2 • Sponsor: Primmune Therapeutics, Inc. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New trial aims to shield hearts from chemo side effects
Prevention Not yet recruitingThis project aims to determine the benefits of the dual SGLT1/2 inhibition as prophylactic treatment to prevent anthracycline-related cardiotoxicity.
Phase: PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Prevention
Last updated Jun 27, 2026 12:30 UTC
-
Can remote monitoring and community support tame postpartum high blood pressure?
Disease control Not yet recruitingThe goal of this randomized clinical trial is to evaluate the effectiveness of a collaborative care intervention, consisting of remote blood pressure monitoring and support from community health workers, in improving blood pressure control and reducing postpartum complications am…
Phase: NA • Sponsor: University of Nebraska • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New artificial vein valve could help millions with leg vein disease
Disease control Not yet recruitingA staged prospective, randomized, non-blinded, multicenter study.
Phase: PHASE2, PHASE3 • Sponsor: Hancock Jaffe Laboratiores, Inc • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope for tough lung cancer: combo therapy enters phase II trial
Disease control Not yet recruitingThis Phase II study is a clinical study exploring the efficacy and safety of BL-M14D1 in combination with Atezolizumab in patients with extensive-stage small cell lung cancer.
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to tame transplant complication
Disease control Not yet recruitingChronic graft-versus-host disease (cGvHD) is a serious condition that can happen after a stem cell or bone marrow transplant. The donor's immune cells attack the patient's body, causing inflammation, pain, and damage to organs like the skin, liver, or lungs. For patients with mod…
Phase: PHASE2 • Sponsor: Dennis Kim • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Could less radiation be enough for some lymphoma patients?
Disease control Recruiting nowThis study is designed to evaluate the efficacy and safety of reduced-intensity radiotherapy for stage I/II low-risk nasal-type NK/T-cell lymphoma that has achieved complete remission after chemotherapy.
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New injections aim to melt liver fat in MASH patients
Disease control Not yet recruitingThe purpose of this study is to investigate the efficacy and safety of HRS-4729 injection and HRS9531 injection in adult participants with metabolic dysfunction-associated steatohepatitis after 52 weeks of treatment.
Phase: PHASE2 • Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New cream targets skin lymphoma without steroids
Disease control Not yet recruitingBackground: CTCL is a rare type of non-Hodgkin lymphoma that primarily affects the skin, causing red patches, plaques, and severe itching. Currently, topical corticosteroids are commonly used for early-stage disease, but long-term application can cause significant skin side effe…
Phase: PHASE2 • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Targeted Antibody-Drug could shrink Hard-to-Treat ovarian cancers
Disease control Not yet recruitingTo observe the efficacy and safety of IMMU-132 in patients with advanced or recurrent ovarian cancer with high TROP-2 expression in tumor tissue, who have failed standard therapy or are unable to receive standard treatment.
Phase: PHASE1 • Sponsor: Shanghai Gynecologic Oncology Group • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could a simple nerve block transform heart surgery recovery?
Symptom relief Not yet recruitingHeart surgery is a complex and delicate procedure that affects more than one million people worldwide each year. Patients who undergo this surgery are generally elderly and have multiple comorbidities, which places them in high-risk categories (ASA III or IV). This frailty, combi…
Phase: NA • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Symptom relief
Last updated Jul 25, 2026 00:00 UTC
-
One pill to tackle three heart risks: could a polypill cut cardiovascular disease?
Disease control Not yet recruitingThe Polypill Approach for Multiple Cardiovascular Risk Factors (PACIF) trial is a multicenter randomized controlled trial that will test the effectiveness and safety of a fixed-dose combination strategy for integrated management of hypertension, dyslipidemia, and diabetes among a…
Phase: NA • Sponsor: China Medical University, China • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Home saliva tests could map Alzheimer's genetic risk across france
Knowledge-focused Recruiting nowALZEVIT is a nationwide, decentralized, digital-first cohort study in France designed to establish a large-scale Apolipoprotein E (APOE) genotyping registry and enable precision prevention strategies for Alzheimer's disease (AD). Sponsored by Firalis SA and conducted in collabora…
Sponsor: Firalis SA • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Sound waves against addiction: helmet zaps brain to curb substance use
Disease control Recruiting nowThe goal of this clinical trial is to evaluate the safety, feasibility, and preliminary clinical benefit of focused ultrasound (FUS) neuromodulation using the FUS Next Generation Dome Helmet (NGDH) in adults with treatment-resistant moderate-to-severe substance use disorder (SUD)…
Phase: NA • Sponsor: Sunnybrook Health Sciences Centre • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Glow-in-the-Dark dye could speed up prostate cancer detection
Diagnosis Not yet recruitingThis study aims to validate the accuracy of the infrared fluorescence rapid detection technique for the diagnosis of prostate biopsy specimens, and to compare it with intraoperative frozen section and conventional paraffin section (the gold standard), so as to evaluate its feasib…
Sponsor: Xiangya Hospital of Central South University • Aim: Diagnosis
Last updated Jul 10, 2026 00:00 UTC
-
Can mapping migrant networks help end neglected tropical diseases?
Disease control Recruiting nowNeglected Tropical Diseases (NTDs) are among the most common groups of diseases affecting over one billion people globally and are disproportionately concentrated in remote, underserved, and marginalized communities. Efforts toward NTD elimination have largely relied on preventiv…
Phase: NA • Sponsor: Uwemedimo Friday Ekpo • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC